about
Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targetingReversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma.High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors.Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth.Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress ResponseTranscriptomic analysis functionally maps the intrinsically disordered domain of EWS/FLI and reveals novel transcriptional dependencies for oncogenesisInvestigating the role of LSD2 as an epigenetic regulator in Ewing sarcoma.
P50
Q26768602-194C4CE2-2FC1-4DEB-811B-90691A4BD7D3Q34340537-AFC15591-60D9-423A-AEF8-609545802829Q35044161-0E5078D6-FE39-4D20-B7A6-C4A61F616B65Q38605150-0BD1DD1F-E061-43D6-86DF-4886C74B8407Q38981458-B89D3D01-EDC8-42F6-A61B-2CC351E2E201Q60035696-12FA9ACF-A7E9-4DBB-B29E-0367B4DE52E1Q64267686-3A3E02EF-FA84-4ED1-A61D-BD69C2C4C5B3Q64899927-AB9739E4-B79B-4231-B9AB-21853A20E53B
P50
description
investigador
@es
researcher
@en
name
Emily R Theisen
@en
type
label
Emily R Theisen
@en
prefLabel
Emily R Theisen
@en
P31
P496
0000-0003-2923-1198